COVID-19 Disrupts Oncology Trials

COVID-19 Disrupts Oncology Trials
COVID-19 disruptions reveal heavy impacts on the global Oncology Phase II clinical trials, as per
GlobalData, a leading data and analytics company. Several factors including delayed initiation, enrollment suspension, and slow enrolment are the known contributing factors for these disruptions.
The
total number of clinical trials that were disrupted showed that slow enrollment was the top reason, followed by enrollment suspension and lastly delayed initiation as reported by
GlobalData's global survey of key opinion leaders in the pharma industry.
"As there are more clinical trials in oncology, it is not surprising that it is the most disrupted of the therapy areas. The main challenge has been providing the necessary cancer care during the pandemic. Finding the necessary resources such as ventilation systems and even staff is an on-going challenge for most healthcare providers. Globally, North America far exceeds all other countries when it comes to multinational and single-country disrupted clinical trials, due to more trials being completed in this region. Europe is second, followed by Asia-Pacific, the Middle East and Africa, and South and Central America," says Scotty Chung-Siu, MPH, Senior Analyst at GlobalData.

Related Keywords

, Oncology Phase , Covid 19 , Pandemic , Ncology , Covid 19 Disruptions , Hase Ii Clinical Trials , Clinical Trials ,